All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?

What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?

In this video, Zeiser explains the mechanism of action of glucagon-like peptide-2 (GLP-2), an enteroendocrine peptide produced by L cells. Studies in mice have shown intestinal GLP-2 levels are reduced in acute (a)GvHD, and similarly in patients developing GvHD. The use of the GLP-2 analog, teduglutide, reduces de novo aGvHD and steroid-refractory aGvHD in different mouse models. Teduglutide may also be effective in patients with steroid-refractory aGvHD.

 

Share: